Cargando…

Effect of a Therapeutic Maximum Allowable Cost (MAC) Program on the Cost and Utilization of Proton Pump Inhibitors in an Employer-Sponsored Drug Plan in Canada

BACKGROUND: Therapeutic maximum allowable cost (MAC) is a managed care intervention that uses reference pricing in a therapeutic class or category of drugs or an indication (e.g., heartburn). Therapeutic MAC has not been studied in Canada or the United States. The proton pump inhibitor (PPI) rabepra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mabasa, Vincent, Ma, Johnny
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2006
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437583/ https://www.ncbi.nlm.nih.gov/pubmed/16792443 http://dx.doi.org/10.18553/jmcp.2006.12.5.371

Ejemplares similares

Utilization and Cost of an Employer-Sponsored Comprehensive Primary Care Delivery Model
por: Basu, Sanjay, et al.
Publicado: (2020)

ENTERING MEDICARE ADVANTAGE FROM EMPLOYER-SPONSORED PLANS: CHANGE IN OUT-OF-POCKET COSTS AND UTILIZATION AT AGE 65
por: Hames, Alexandra Glynn, et al.
Publicado: (2022)

The Costs of Industry-Sponsored Drug Trials in Canada
por: Tran, Dat T., et al.
Publicado: (2019)

Evaluation of the Maximum Allowable Cost Program
por: Lee, A. James, et al.
Publicado: (1983)

Employer and Plan Sponsor Views on Pharmacy Reimbursement
por: Stull, Michael, et al.
Publicado: (2020)

Medical Costs of Substance Use Disorders in the US Employer-Sponsored Insurance Population
por: Li, Mengyao, et al.
Publicado: (2023)

Comparison of Mail-Order With Community Pharmacy in Plan Sponsor Cost and Member Cost in Two Large Pharmacy Benefit Plans
por: Johnsrud, Michael, et al.
Publicado: (2007)

Heartburn in Consumer-Directed Health Care and the Cost Outcomes of Therapeutic Maximum Allowable Cost
por: Curtiss, Frederic R.
Publicado: (2006)

Improving Colorectal Cancer Screening at an Employer-Sponsored Health Plan During the COVID-19 Pandemic
por: Kim, Jeniffer S., et al.
Publicado: (2022)

Costs of Specialist Referrals From Employer-Sponsored Integrated Health Care Clinics Are Lower Than Those From Community Providers
por: Wright, John R., et al.
Publicado: (2022)

Environmental Costs of Government-Sponsored Agrarian Settlements in Brazilian Amazonia
por: Schneider, Maurício, et al.
Publicado: (2015)

The Costs of Industry-Sponsored Medical Device Clinical Trials in Alberta
por: Akpinar, Ilke, et al.
Publicado: (2019)

Prescribing patterns and economic costs of proton pump inhibitors in Colombia
por: Machado-Alba, Jorge, et al.
Publicado: (2013)

Effects on the Cost and Utilization of Proton Pump Inhibitors From Adding Over-the Counter Omeprazole to Drug Benefit Coverage in a State Employee Health Plan
por: Harris, Brittany N., et al.
Publicado: (2004)

Mac OS X maximum security
por: Ray, John, et al.
Publicado: (2003)

Relationship Between Adherence to Antihypertensive Medication Regimen and Out-of-Pocket Costs Among People Aged 35 to 64 With Employer-Sponsored Health Insurance
por: Baker-Goering, Madeleine M., et al.
Publicado: (2019)

Vaping in the Workplace: Implications for Employer-Sponsored Tobacco Cessation Programs
por: Graham, Amanda L., et al.
Publicado: (2020)

Proton pump inhibitors: potential cost reductions by applying prescribing guidelines
por: Cahir, Caitriona, et al.
Publicado: (2012)

The costly case of proton-pump inhibitors: a single-center experience
por: Suresh Kumar, Vishnu Charan, et al.
Publicado: (2020)

Maximum Contribution to the Cost of the Basic Programme
Publicado: (1967)

Maximum Contribution to the Cost of the Basic Programme
Publicado: (1967)

Maximum Contribution to the Cost of the Basic Programme
Publicado: (1971)

A 30-Month Evaluation of the Effects on the Cost and Utilization of Proton Pump Inhibitors From Adding Omeprazole OTC to Drug Benefit Coverage in a State Employee Health Plan
por: West, Donna S., et al.
Publicado: (2006)

Five-Year Examination of Utilization and Drug Cost Outcomes Associated with Benefit Design Changes Including Reference Pricing for Proton Pump Inhibitors in a State Employee Health Plan
por: Johnson, Jill
Publicado: (2011)

Heuristics for Two Depot Heterogeneous Unmanned Vehicle Path Planning to Minimize Maximum Travel Cost
por: Bae, Jungyun, et al.
Publicado: (2019)

Comparison of Prices for Commonly Administered Drugs in Employer-Sponsored Insurance Relative to Medicare
por: Chang, Jessica Y., et al.
Publicado: (2023)

Healthcare Resource Utilization and Cost of Invasive Meningococcal Disease in Ontario, Canada
por: Rampakakis, Emmanouil, et al.
Publicado: (2019)

Difference in drug cost between private and public drug plans in Quebec, Canada
por: M., Chamoun, et al.
Publicado: (2022)

A randomised controlled trial to prevent smoking relapse among recently quit smokers enrolled in employer and health plan sponsored quitlines
por: McDaniel, Anna M, et al.
Publicado: (2015)

Lessons from clinical implementation of a preemptive pharmacogenetic panel as part of a testing pilot program with an employer-sponsored medical plan
por: Norris, Madeline, et al.
Publicado: (2023)

Comparison of health care resource utilization and costs among patients with GERD on once-daily or twice-daily proton pump inhibitor therapy
por: Mody, Reema, et al.
Publicado: (2013)

Maximum Percentage Contribution to the Cost of the Basic Programme
Publicado: (1971)

Maximum Percentage Contribution to the Cost of the Basic Programme
Publicado: (1971)

Shifting paradigms: Reframing coverage of antiobesity medications for plan sponsors
por: Green, Libbi, et al.
Publicado: (2023)

Genetic testing and employer‐sponsored wellness programs: An overview of current vendors, products, and practices
por: McDonald, Whitney S., et al.
Publicado: (2020)

Gaps in Dyslipidemia Care Among Working‐Aged Individuals With Employer‐Sponsored Health Care
por: Shiffman, Dov, et al.
Publicado: (2020)

Sources of Geographic Variation in Health Care Spending Among Individuals With Employer Sponsored Insurance
por: Johnson, William C., et al.
Publicado: (2020)

Variability in Prices Paid for Hemodialysis by Employer-Sponsored Insurance in the US From 2012 to 2019
por: League, Riley J., et al.
Publicado: (2022)

Diagnosed Prevalence and Incidence of Vitiligo in the United States: Analysis of Employer-Sponsored Insurance Claims
por: Ray, Markqayne, et al.
Publicado: (2023)

Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment of reflux esophagitis in China
por: Wang, Zhenhua, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o1cak2idkvqvs6phd833hp5a02